相关实验视频
Updated: Jul 18, 2025

Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
对贝尔祖提凡的群体药理动力学分析,以告知剂量考虑和标签
Dhananjay D Marathe1, Petra M Jauslin2, Huub Jan Kleijn2
1Merck & Co., Inc., Rahway, New Jersey, USA.
贝尔祖提凡是一种低氧诱导的2α因子抑制剂,在VHL患者中显示出可预测的药理动力学. 对于UGT2B17和CYP2C19酶的双重低代谢者,药物暴露显著增加.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药理学 临床药理学
- 在瘤学瘤学.
背景情况:
- 贝尔祖提凡是一种口服低氧诱导的2α因子抑制剂,已被批准用于与希佩尔-林道氏病 (VHL) 相关的癌症.
- 主要新陈代谢通过尿素5'-二-葡萄糖转移酶 (UGT) 2B17和细胞染色体 (CYP) 2C19.19发生.
研究的目的:
- 为了表征贝尔祖提凡的群体药理动力学 (PK).
- 评估各种协同变量的对贝尔祖提凡PK的影响.
- 为了告知贝尔祖提凡标签关于药物暴露和遗传多态性.
主要方法:
- 使用NONMEM 7.3.3开发了一个人群PK模型.
- 利用了从临床药理和临床研究中获得的VHL疾病和其他固体瘤患者的数据.
- 分析了包括人口统计,器官损伤和遗传多态度在内的共变效应.
主要成果:
- 贝尔祖提凡PK被描述为一个两部分模型,具有第一阶段的吸收和排泄.
- 根据年龄,性别,体重,脏或肝功能障碍,没有观察到临床显著的PK差异.
- 与广泛代谢剂相比,双重UGT2B17和CYP2C19低代谢剂的血度-时间曲线下的面积增加了3.2倍.
结论:
- 贝尔祖提凡PK的特征很好,通常不受常见共变量的影响.
- 在UGT2B17和CYP2C19的遗传变异显著影响贝尔祖提凡暴露,特别是在双重低代谢者.
- 这些发现支持贝尔祖提凡的优化剂量和治疗监测策略.
更多相关视频
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Analysis of Population Pharmacokinetic Data
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .